CD19 and B-cell chronic lymphocytic leukemia: So far, frequent, durable and objective regression in pediatric B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B cell lymphoma have been reported using anti-CD19 CARs (59–62).